4,901 trials
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo) — 16026; 5740; 19809 hours*ng/mL
Healthy Subjects (HS)
Primary: Number of Participants With Adverse Events (AEs) — 7 Participants
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter
Healthy
Primary: Maximum Observed (Plasma) Concentration (Cmax) of Total Molybdenum — 173.10; 174.27 nanograms (ng)/milliliter (mL)
Depression · Anxiety · Psychological Distress
Primary: Randomization Rate: Number of Participants Who Were Randomized and Completed EMA Assessments and Activities in the HMP App — 46; 46 Participants
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo) — 14531; 18537; 14536 hours*ng/mL
Hepatic Impairment · Moderate Impaired Hepatic Function
Primary: Maximum Plasma Concentration (Cmax) of Quizartinib Following Single Dose of Quizartinib in Participants With Moderate Hepatic Impairment Compared to Participants With…
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Tepotinib in Treatment A and Treatment C — 21722; 23649…
Aging
Primary: Walking Speed Change From Baseline — .054; .078; .085; .039 meters/second
Renal Insufficiency
Primary: Total Daily Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours at Steady-state (AUC0-24,ss) of Aztreonam (ATM) — 922.9; 733.5 Microgram*hour per…
Healthy
Primary: Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification…
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) on Day 1 & 4 of Aztreonam — 69.44; 79.66 micrograms per milliliter (ug/mL)
Healthy
Primary: Dose-normalized Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 117.15…
Lymphoblastic Leukemia, Acute, Childhood · Lymphoblastic Lymphoma · Peripheral T-cell Lymphoma
Primary: Number of Patients That Experienced DLT During Cycle 1 of Therapy — 3; 3; 5; 3 Participants
Pharmacokinetics · Safety Issues
Primary: Peak Serum Concentration of Bevacizumab (Cmax) — 22144.83; 21540; 22566.67 ng/ml — p=0.9766